Lorusso, Domenica http://orcid.org/0000-0003-0981-0598
Maltese, Giuseppa
Sabatucci, Ilaria
Cresta, Sara
Matteo, Cristina
Ceruti, Tommaso
D’Incalci, Maurizio
Zucchetti, Massimo
Raspagliesi, Francesco
Sonetto, Cristina
Sinno, Valentina
Ronzulli, Dominique
Giolitto, Serena
de Braud, Filippo
Funding for this research was provided by:
Clovis Oncology
Università Cattolica del Sacro Cuore
Article History
Accepted: 13 November 2020
First Online: 28 December 2020
Declarations
:
: Open access funding provided by Università Cattolica del Sacro Cuore within the CRUI-CARE Agreement. Clovis Oncology supported the trial with financial support for PK evaluation and editorial support, and by providing rucaparib free of charge.
: Domenica Lorusso has served in a consulting or advisory role for Clovis Oncology, Amgen, AstraZeneca, ImmunoGen, Genmab, Merck, PharmaMar, Roche, Takeda, and Tesaro; received support for travel or accommodation from AstraZeneca, PharmaMar, Roche, and Tesaro; has served as a principal investigator of trials for Clovis Oncology, AstraZeneca, Immunogen, Genmab, Merck, PharmaMar, Roche, and Tesaro; and her institution has received research grants from Clovis Oncology, Merck, PharmaMar, Roche, and Tesaro. Maurizio D’Incalci has served in a consulting or advisory role for Tesaro and PharmaMar. Filippo de Braud has served in a consulting or advisory role for Regione Toscana and Servier; received support for travel or accommodation from Amgen, BMS, Celgene, and Roche; received fees for review activities such as data monitoring boards from BMS, Daiichi Sankyo, EMD Serono, Incyte, Ignyta, Nerviano Medical Science (NMS), OCTIMET Oncology, Pfizer, Pharma Research Associates; Pierre Fabre, Roche, Sanofi, and Teofarma; and reports other support (e.g., writing assistance, administrative support) from AccuMed, Bayer, Biotechspert, BMS, Celgene, Dephaforum, Healthcare Research & Pharmacoepidemiology, Ignyta, Loxo Oncology, Merck, MSD, Pfizer, prIME Oncology, Roche, Sanofi, and Servier. Giuseppa Maltese, Ilaria Sabatucci, Sara Cresta, Cristina Matteo, Tommaso Ceruti, , Massimo Zucchetti, Francesco Raspagliesi, Cristina Sonetto, Valentina Sinno, Dominique Ronzulli, and Serena Giolitto have no conflicts of interest that are directly relevant to the content of this article.
: The trial was approved by the Fondazione IRCCS National Cancer Institute of Milan Ethical Committee.
: Patients provided written informed consent before participating in the study.
: Not applicable.
: Further data are available from the corresponding author upon request.
: Not applicable.
: DL designed the study. GM, IS, SC, FR, CS, VS, DR, and SG collected the data. DL, CM, TC, MD, MZ, and FdB analyzed the data. All authors contributed to the interpretation of the data and critically revised the manuscript for important intellectual content. All authors provided final approval of the manuscript and agreed to be accountable for the accuracy and integrity of this work.